CD34+自体干细胞移植联合DC-CIK细胞免疫治疗复发难治性淋巴瘤疗效观察

Effect Observation of CD34 + Autologous Stem Cell Transplantation Combined with DC-CIK Cell Immunotherapy in Treatment of Patients with Recurrent and Refractory Lymphoma

目的研究CD34+自体造血干细胞移植联合树突细胞-细胞因子诱导杀伤细胞(DC-CIK)免疫治疗复发难治性淋巴瘤的临床疗效及安全性。方法选择2011年1月—2014年5月48例复发难治性淋巴瘤患者作为研究对象,按临床治疗方法分为对照组和观察组,每组24例,对照组在淋巴瘤常规治疗基础上加用CD34+自体干细胞移植治疗,观察组在对照组基础上联合DC-CIK细胞免疫治疗。治疗结束后比较评价两组临床疗效、不良反应以及预后情况。结果观察组临床总有效率明显高于对照组(P<0.05)。两组治疗期间不良反应发生率比较差异无统计学意义(P>0.05)。观察组平均生存时间20个月,中位生存时间18个月;对照组平均生存时间16个月,中位生存时间14个月。观察组总体生存率明显高于对照组(P<0.05)。结论 CD34+自体造血干细胞移植联合DC-CIK细胞免疫治疗复发难治性淋巴瘤患者可取得较好的临床疗效,安全性高,不良反应少,且预后效果尚可。

Objective To study clinical efficacy and safety of CD34 ＋ autologous hematopoietic stem cell transplantation combined with dendritic cells and cytokine-induced killer （DC-CIK） ceils immunotherapy in treatment of pa- tients with recurrent and refractory lymphoma. Methods A total of 48 patients with recurrent and refractory lymphoma during January 2011 and May 2014 were divided into control group and observation group according to clinical treatment methods （n = 24 for each group）. Control group was added with CD34 ＋ autologous stem cell transplantation on the basis of routine treatment for lymphoma, and observation group was added with DC-CIK cells immunotherapy on the basis of treatment for control group. Clinical efficacy, adverse reaction and prognosis were evaluated and compared after treatment in two groups. Results The total effective rate in observation group was significantly higher than that in control group （P 〈 0.05）. There was no significant difference in incidence rate of adverse reactions between the two groups （P 〉 0. 05 ）. The average survival times and median survival times were 20 months and 18 months in observation group and 16 months and 14 months in control group respectively. The overall survival rate in observation group was significantly higher than that in control group （P 〈 0. 05）. Conclusion CD34 ＋ autologous hematopoietic stem cell transplantation com- bined with DC-CIK ceils immunotherapy in treatment of patients with recurrent and refractory lymphoma can achieve better clinical efficacy, high safety, less adverse reaction and acceptable prognosis.